Point Biopharma Global Inc.

Plus: Pair of cash-rich biotechs agree to combine, and Australian radiopharma company Advancell follows venture round by expanding Lilly relationship

Itm and Perspective’s readouts are the latest clinical advances in GEP-NETs, the first indication to put radioligand therapies on the map

Decisions about manufacturing and distribution could be make-or-break for drug developers producing their own lead-212 

The ɑ-emitting radioisotope’s rapid decay has logistical drawbacks, but its supply could beat actinium-225’s on scale

Plus: AbbVie buys Celsius; Fosun offers to take Henlius subsidiary private; Coherus divests biosimilar of Humira

Largest upfront M&A payment for a preclinical biotech in three years 

Pluvicto’s steep launch appears on track to surpass $1B in sales this year

Deal brings more momentum for α-emitters, with Fusion’s lead program contrasting Novartis’ β-emitting Pluvicto

The manufacturing-focused radiopharma met its primary endpoint but fell short of Novartis on rPFS; both companies face the same OS challenge

Target, ligand and radioisotope choices fuel the growing field